Aoxin Q&M posts FY2025 net profit after tax of CNY6.9 million as FY2024 net loss of CNY8.0 million reverses to profit

Reuters
02/28
Aoxin Q&M posts FY2025 net profit after tax of CNY6.9 million as FY2024 net loss of CNY8.0 million reverses to profit

Aoxin Q&M Dental reported FY2025 net profit after tax of RMB6.9 million, compared with a net loss in FY2024, as it cited a substantial reduction in losses from its share of results of an associate. FY2025 revenue was RMB171.0 million (down 3.6%), while FY2025 EBITDA was RMB24.1 million. Net profit after tax excluding share of results of associate was RMB7.0 million (up 11.6%). In 2H2025, revenue was RMB84.2 million (down 10.8%) and net profit after tax was RMB4.2 million. The share of results of associate in FY2025 was a loss of RMB0.03 million. As at 31 December 2025, net assets were RMB349.3 million and cash and cash equivalents were RMB148.7 million following completion of a rights issue that raised net proceeds of RMB82.8 million. The group said it plans to allocate RMB43.7 million of the proceeds for business expansion, including mergers and acquisitions, joint ventures and partnerships, and RMB27.3 million for investment in property, plant and equipment, while also highlighting expansion of its lab services business into Singapore and other regional countries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aoxin Q&M Dental Group Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: R326Z1ZBSHNEBOJL) on February 28, 2026, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10